Stempoint Capital LP reported 71 positions worth $533.46M for the quarter ended Sep 30, 2026, down 7.5% on the prior quarter. It opened 29 new positions, added to 18, trimmed 22 and exited 30. Its largest holding is Scholar Rock Holding Corp at 6.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| SRRK Scholar Rock Holding Corp | +449.8K | +188.1% | $21.73M | 6.24% |
| ADPT Adaptive Biotechnologies Corp | +463.6K | – | $13.40M | 2.51% |
| IMTX Immatics N.V. | +1.31M | – | $11.49M | 2.15% |
| GRAL GRAIL, Inc. | +81.9K | – | $11.48M | 2.15% |
| ACRS Aclaris Therapeutics, Inc. | +2.05M | – | $10.79M | 2.02% |
| ROIV Roivant Sciences Ltd. | +293.1K | +84.1% | $10.72M | 4.4% |
| ERAS Erasca, Inc. | +694.7K | +44.4% | $10.18M | 6.21% |
| CCCC C4 Therapeutics, Inc. | +2.77M | +528.9% | $9.22M | 2.06% |
| ONC BeOne Medicines Ltd. | +25.1K | – | $9.17M | 1.72% |
| JNJ Johnson & Johnson | +30.0K | – | $7.94M | 1.49% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | -109.9K | -68.7% | $22.57M | 1.92% |
| TYRA Tyra Biosciences, Inc. | -632.8K | -100.0% | $20.21M | Exited |
| KNSA Kiniksa Pharmaceuticals International, plc | -157.4K | -75.2% | $11.75M | 0.725% |
| BIOA BioAge Labs, Inc. | -464.2K | -100.0% | $11.38M | Exited |
| MLYS Mineralys Therapeutics, Inc. | -402.7K | -66.8% | $10.12M | 0.942% |
| CLYM Climb Bio, Inc. | -742.7K | -100.0% | $9.69M | Exited |
| BHVN Biohaven Ltd. | -667.3K | -62.7% | $8.91M | 0.993% |
| ZURA Zura Bio Ltd | -1.37M | -100.0% | $8.07M | Exited |
| ORKA Oruka Therapeutics, Inc. | -89.2K | -76.6% | $7.43M | 0.426% |
| CGON CG Oncology, Inc. | -104.6K | -65.6% | $7.41M | 0.728% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ADPT Adaptive Biotechnologies Corp | +463.6K | $13.40M | 2.51% |
| IMTX Immatics N.V. | +1.31M | $11.49M | 2.15% |
| GRAL GRAIL, Inc. | +81.9K | $11.48M | 2.15% |
| ACRS Aclaris Therapeutics, Inc. | +2.05M | $10.79M | 2.02% |
| ONC BeOne Medicines Ltd. | +25.1K | $9.17M | 1.72% |
| JNJ Johnson & Johnson | +30.0K | $7.94M | 1.49% |
| TRVI Trevi Therapeutics, Inc. | +552.2K | $7.91M | 1.48% |
| LLY ELI LILLY & Co | +6,599 | $7.64M | 1.43% |
| CERS Cerus Corp | +2.97M | $7.06M | 1.32% |
| JBIO Jade Biosciences, Inc. | +471.7K | $6.63M | 1.24% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| TYRA Tyra Biosciences, Inc. | -632.8K | $20.21M | 3.5% |
| BIOA BioAge Labs, Inc. | -464.2K | $11.38M | 1.97% |
| CLYM Climb Bio, Inc. | -742.7K | $9.69M | 1.68% |
| ZURA Zura Bio Ltd | -1.37M | $8.07M | 1.4% |
| AMLX Amylyx Pharmaceuticals, Inc. | -384.3K | $6.90M | 1.2% |
| CLDX Celldex Therapeutics, Inc. | -178.4K | $6.64M | 1.15% |
| EQ Equillium, Inc. | -2.02M | $6.45M | 1.12% |
| DFTX Definium Therapeutics, Inc. | -137.1K | $6.45M | 1.12% |
| IVA Inventiva S.A. | -1.43M | $5.39M | 0.935% |
| EYPT EyePoint, Inc. | -338.5K | $4.84M | 0.839% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRRK Scholar Rock Holding Corp | Healthcare | 689.0K | $33.29M | 6.24% | +449.8K | +188.1% | Added | 0.52% |
| 2 | ERAS Erasca, Inc. | Healthcare | 2.26M | $33.14M | 6.21% | +694.7K | +44.4% | Added | 0.65% |
| 3 | ABVX Abivax S.A. | Healthcare | 279.4K | $27.67M | 5.19% | -4,259 | -1.5% | Reduced | 0.35% |
| 4 | TNGX Tango Therapeutics, Inc. | Healthcare | 989.3K | $24.68M | 4.63% | -233.7K | -19.1% | Reduced | 0.57% |
| 5 | ROIV Roivant Sciences Ltd. | Healthcare | 641.5K | $23.46M | 4.4% | +293.1K | +84.1% | Added | 0.09% |
| 6 | TRAX First Tracks Biotherapeutics, Inc. | Healthcare | 649.9K | $23.03M | 4.32% | +27.2K | +4.4% | Added | 1.81% |
| 7 | ELVN Enliven Therapeutics, Inc. | Healthcare | 330.5K | $15.15M | 2.84% | -16.4K | -4.7% | Reduced | 0.42% |
| 8 | ALKS Alkermes plc. | Healthcare | 333.3K | $13.51M | 2.53% | +85.3K | +34.4% | Added | 0.2% |
| 9 | ADPT Adaptive Biotechnologies Corp | Healthcare | 463.6K | $13.40M | 2.51% | +463.6K | – | New | 0.29% |
| 10 | DNTH Dianthus Therapeutics, Inc. | Healthcare | 150.8K | $13.28M | 2.49% | -50.1K | -24.9% | Reduced | 0.26% |
| 11 | SYRE Spyre Therapeutics, Inc. | Healthcare | 132.2K | $11.77M | 2.21% | +25.3K | +23.7% | Added | 0.15% |
| 12 | IMTX Immatics N.V. | Healthcare | 1.31M | $11.49M | 2.15% | +1.31M | – | New | 0.91% |
| 13 | GRAL GRAIL, Inc. | Healthcare | 81.9K | $11.48M | 2.15% | +81.9K | – | New | 0.18% |
| 14 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 38.7K | $11.28M | 2.11% | +1,477 | +4.0% | Added | 0.13% |
| 15 | SRZN Surrozen, Inc. | Healthcare | 418.5K | $11.12M | 2.08% | -184.3K | -30.6% | Reduced | 3.55% |
Tip. Select a row to see that position’s full history at Stempoint Capital.
As of its Q3 2026 13F filing, Stempoint Capital LP’s five largest positions were Scholar Rock Holding Corp (SRRK) at 6.2%, Erasca, Inc. (ERAS) at 6.2%, Abivax S.A. (ABVX) at 5.2%, Tango Therapeutics, Inc. (TNGX) at 4.6%, Roivant Sciences Ltd. (ROIV) at 4.4% of the reported portfolio.
Stempoint Capital LP reported a 13F portfolio worth $533.46M across 71 positions for Q3 2026. That is down 7.5% from the previous quarter.
Its largest purchases by value were Scholar Rock Holding Corp ($21.73M), Adaptive Biotechnologies Corp ($13.40M), Immatics N.V. ($11.49M). It opened 29 new positions.
Its largest sales by value were Revolution Medicines, Inc. ($22.57M), Tyra Biosciences, Inc. ($20.21M), Kiniksa Pharmaceuticals International, plc ($11.75M). It exited 30 positions entirely.
From the Form 13F-HR reports Stempoint Capital LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.